Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 4/20 | 0.56 |
| ▸ | FEN1 | P39748 | 4/20 | 0.56 |
| ▸ | RBP4 | P02753 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205323 | 1.00 | ALOX5AP (0.56) | ALOX5APFEN1RBP4KDM4EPKM | |
| SCHEMBL19205332 | 0.98 | ALOX5AP (0.54) | ALOX5APFEN1RBP4KDM4EPKM | |
| SCHEMBL19205333 | 0.98 | ALOX5AP (0.54) | ALOX5APFEN1RBP4KDM4EPKM | |
| SCHEMBL19205402 | 0.98 | ALOX5AP (0.54) | ALOX5APFEN1RBP4KDM4EPKM | |
| SCHEMBL19205390 | 0.97 | RBP4 (0.54) | ALOX5APFEN1RBP4KDM4EPKM | |
| SCHEMBL19205388 | 0.97 | RBP4 (0.54) | ALOX5APFEN1RBP4KDM4EPKM | |
| SCHEMBL19205404 | 0.86 | RBP4 (0.56) | ALOX5APFEN1RBP4SCN9AGPR119 | |
| SCHEMBL19205428 | 0.85 | RBP4 (0.57) | RBP4SSTR1SSTR4MEN1KMT2A | |
| SCHEMBL20744476 | 0.84 | RBP4 (0.54) | ALOX5APFEN1RBP4KDM4EPKM | |
| SCHEMBL27157756 | 0.84 | RBP4 (0.54) | ALOX5APFEN1RBP4KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210971-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| EP-3210971-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | ALOX5AP 2617/4885FEN1 3383/4885RBP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.